Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from Hansa Biopharma AB ( (SE:HNSA) ).
Hansa Biopharma has presented positive five-year follow-up results from its study on imlifidase in kidney transplantation at the ESOT Congress 2025. The study demonstrated sustained positive outcomes, with a 90% patient survival rate and 82% graft survival rate, indicating that imlifidase is a viable option for highly sensitized patients, providing long-term benefits comparable to standard kidney transplants.
The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK143.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
More about Hansa Biopharma AB
Hansa Biopharma AB is a biotechnology company that focuses on developing innovative treatments for rare immunological conditions. Their primary product, Imlifidase, is used in the desensitization of highly sensitized kidney transplant patients, enabling successful transplantation by targeting and cleaving immunoglobulin G antibodies.
Average Trading Volume: 205,049
Current Market Cap: SEK2.28B
See more data about HNSA stock on TipRanks’ Stock Analysis page.